4.7 Article

PRADA: Portable Reusable Accurate Diagnostics with nanostar Antennas for multiplexed biomarker screening

Journal

Publisher

WILEY
DOI: 10.1002/btm2.10165

Keywords

biodiagnostic; biosensor; cardiac troponin I; gold nanostars; multiplexing; neuropeptide Y; reusable; surface enhanced Raman

Funding

  1. National Science Foundation [CMMI-1634856]
  2. National Center for Advancing Translational Sciences CTSA award
  3. CDMRP Peer Reviewed Cancer Research Program [W81XWH1810139]
  4. NSF [EPS 1004083]
  5. Department of Education for Graduate Assistance in Areas of National Need (GAANN) Fellowship [P0200A090323]
  6. U.S. Department of Defense (DOD) [W81XWH1810139] Funding Source: U.S. Department of Defense (DOD)

Ask authors/readers for more resources

Precise monitoring of specific biomarkers in biological fluids with accurate biodiagnostic sensors is critical for early diagnosis of diseases and subsequent treatment planning. In this work, we demonstrated an innovative biodiagnostic sensor, portable reusable accurate diagnostics with nanostar antennas (PRADA), for multiplexed biomarker detection in small volumes (similar to 50 mu l) enabled in a microfluidic platform. Here, PRADA simultaneously detected two biomarkers of myocardial infarction, cardiac troponin I (cTnI), which is well accepted for cardiac disorders, and neuropeptide Y (NPY), which controls cardiac sympathetic drive. In PRADA immunoassay, magnetic beads captured the biomarkers in human serum samples, and gold nanostars (GNSs) antennas labeled with peptide biorecognition elements and Raman tags detected the biomarkers via surface-enhanced Raman spectroscopy (SERS). The peptide-conjugated GNS-SERS barcodes were leveraged to achieve high sensitivity, with a limit of detection (LOD) of 0.0055 ng/ml of cTnI, and a LOD of 0.12 ng/ml of NPY comparable with commercially available test kits. The innovation of PRADA was also in the regeneration and reuse of the same sensor chip for similar to 14 cycles. We validated PRADA by testing cTnI in 11 de-identified cardiac patient samples of various demographics within a 95% confidence interval and high precision profile. We envision low-cost PRADA will have tremendous translational impact and be amenable to resource-limited settings for accurate treatment planning in patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available